Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Background: Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. Methods: In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were randomly assigned and received treatment with single-dose psilocybin (0.3 mg/kg) or niacin, both in conjunction with psychotherapy. The primary outcomes were anxiety and depression assessed between groups prior to the crossover at 7 weeks. Results: Prior to the crossover, psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness, improved spiritual wellbeing, and increased quality of life. At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression. Conclusions: In conjunction with psychotherapy, single moderate-dose psilocybin produced rapid, robust and enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress. Trial Registration: ClinicalTrials.gov Identifier: NCT00957359
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both participants and their friends and family reported positive effects on attitude towards life and the self, spiritual well-being, social contacts, quality of life, acceptance of death, and optimism (Ross et al., 2016).”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Ross et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite efforts to employ “active placebos” (e.g., niacin or a low-dose of a psychedelic) (40, 220), many patients and clinicians can still correctly distinguish between a high dose of a psychedelic drug and an active placebo.”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [220]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and with diminished anxiety and depression in terminal cancer patients (Griffiths et al., 2016;Ross et al., 2016;Barrett et al., 2020).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Ross et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psilocybin shows promise as a treatment for major depressive disorder (MDD).”
From Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“recent studies suggesting that psilocybin engenders a rapid antidepressant response that far outlasts the presence of the drug in the body.”
From Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial (2023) · cites this paper as [8]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
(2013) · Cited by 44,563
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988) · Clinical Psychology Review · doi:10.1016/0272-7358(88)90050-5 · Cited by 11,696 · cited 2×
“cancer); Beck Depression Inventory (BDI) (Beck et al., 1988) self-report depression measure; Spielberger State-Trait Anxiety Inventory (STAI) (Spielberger, 1983) self-report measure of state (STAI state or STAI S) and trait (STAI trait or STAI T) anxiety.”
BackgroundMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Mitchell, A. J., Chan, M., Bhatti, H., Halton, M., Grassi, L., Johansen, C., & Meader, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70002-x · Cited by 2,449 · cited 1×
“Enduring clinically significant anxiety and/or depressive symptoms are common in patients with cancer, present in 30–40% of patients in hospital settings (Mitchell et al., 2011).”
BackgroundManual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire"
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970) · Consulting Psychologists Press eBooks · Cited by 2,352
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241 · cited 7×
“The former is significant because depressive symptoms have been associated with increased activity in the medial PFC (Drevets et al., 2008; Farb et al., 2011) and normalization of medial PFC activity has been demonstrated with anti-depressant treatment (Deakin et al., 2008; Holtzheimer and Mayberg, 2011; Kennedy et al…”
BackgroundInfluentialGreicius, M. D., Flores, B. H., Menon, V., Glover, G. H., Solvason, H. B., Kenna, H., Reiss, A. L., & Schatzberg, A. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.020 · Cited by 2,214
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 6×
“…transient near-psychotic symptoms) attributable to psilocybin are all known AEs of psilocybin, were transient, tolerable, and consistent with prior trials of psilocybin administration in normal volunteers (Griffiths et al., 2006, 2008, 2011), and patients with terminal cancer (Grob et al., 2011).”
BackgroundResultInfluentialNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“In two recently published open-label trials, one using a single dose of ayahuasca (Osorio et al., 2015) and the other using two doses of oral psilocybin (Carhart-Harris et al., 2016), acute and enduring anti-depressant effects were reported.”
BackgroundResultThe construction and validation of a death anxiety scale
Templer, D. I. (1970) · The Journal of General Psychology · doi:10.1080/00221309.1970.9920634 · Cited by 1,421
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 11×
“Building upon hallucinogen research with cancer patients from over four decades ago, two recently published randomized controlled trials (RCTs) with serotoninergic psychedelics to treat cancer-related psychological distress, one using psilocybin in patients with advanced-stage cancer conducted at Harbor-UCLA (Grob et…”
BackgroundMethodResultInfluentialHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“…corroborated by recent open-label trials using psilocybin-assisted psychotherapy to treat tobacco addiction (Garcia-Romeu et al., 2014; Johnson et al., 2014) and alcoholism (Bogenschutz et al., 2015) showing significant correlations between the mystical experience and improved clinical outcomes.”
BackgroundDepression, Hopelessness, and Desire for Hastened Death in Terminally Ill Patients With Cancer
Breitbart, W. (2000) · JAMA · doi:10.1001/jama.284.22.2907 · Cited by 1,110 · cited 2×
“With a growing body of evidence linking higher levels of existential/spiritual wellbeing (in cancer patients) with improved quality of life and decreased depression/hopelessness/suicidality (Breitbart et al., 2000; McClain et al., 2003; Nelson et al., 2002), the need to develop effective therapeutic approaches to miti…”
BackgroundPsilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 2×
“It is further corroborated by recent open-label trials using psilocybin-assisted psychotherapy to treat tobacco addiction (Garcia-Romeu et al., 2014; Johnson et al., 2014) and alcoholism (Bogenschutz et al.”
BackgroundGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Development of the WHOQOL: Rationale and Current Status
Group, W. (1994) · International Journal of Mental Health · doi:10.1080/00207411.1994.11449286 · Cited by 888
A case for including spirituality in quality of life measurement in oncology
Brady, M. J., Peterman, A. H., Fitchett, G., Mo, M., & Cella, D. (1999) · Psycho-Oncology · doi:10.1002/(sici)1099-1611(199909/10)8:5<417::aid-pon398>3.0.co;2-4 · Cited by 835
Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients
McClain, C. S., Rosenfeld, B., & Breitbart, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13310-7 · Cited by 812 · cited 2×
“With a growing body of evidence linking higher levels of existential/spiritual wellbeing (in cancer patients) with improved quality of life and decreased depression/hopelessness/suicidality (Breitbart et al., 2000; McClain et al., 2003; Nelson et al., 2002), the need to develop effective therapeutic approaches to miti…”
BackgroundGasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 2×
“…psilocybin in patients with advanced-stage cancer conducted at Harbor-UCLA (Grob et al., 2011) and the other using LSD in patients with a variety of life-threatening illnesses including but not limited to cancer diagnoses (Gasser et al., 2014), suggested acute and sustained treatment benefits.”
BackgroundThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Breitbart, W., Rosenfeld, B., Gibson, C., Pessin, H., Poppito, S., Nelson, C., Tomarken, A., Timm, A. K., Berg, A., Jacobson, C., et al. (2010) · Psycho-Oncology · doi:10.1002/pon.1556 · Cited by 704
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Depression, rumination and the default network
Berman, M. G., Peltier, S., Nee, D. E., Kross, E., Deldin, P. J., & Jonides, J. (2011) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsq080 · Cited by 568
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 553
Role of Neurotrophic Factors in the Etiology and Treatment of Mood Disorders
Duman, R. S. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:1:011 · Cited by 537
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 5×
“There were no serious adverse cardiac events, consistent with psilocybin’s absence of cardiac toxicity when administered in controlled laboratory settings (Studerus et al., 2011).”
BackgroundInfluentialAGHAJANIAN, G. K., & MAREK, G. J. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00051-8 · Cited by 514
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Vaidya, V. A., Marek, G. J., Aghajanian, G. K., & Duman, R. S. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02785.1997 · Cited by 479
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
The demoralization scale: a report of its development and preliminary validation
Kissane, D. W., Wein, S., Love, A., Lee, X. Q., Kee, P. L., & Clarke, D. M. (2004) · Journal of Palliative Care · doi:10.1177/082585970402000402 · Cited by 442 · cited 2×
“Cancer-related existential distress (demoralization, hopelessness, attitudes and affect associated with disease progression and death) was assessed at baseline, 2 weeks post-dose 1, and 26 weeks post-dose 2: Demoralization (DEM) scale (Kissane et al., 2004), self-report measure of the cancer-related demoralization syn…”
BackgroundStuck in a rut: rethinking depression and its treatment
Holtzheimer, P. E., & Mayberg, H. S. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2010.10.004 · Cited by 430
Cortical 5-HT 2A Receptor Signaling Modulates Anxiety-Like Behaviors in Mice
Weisstaub, N. V., Zhou, M., Lira, A., Lambe, E., González-Maeso, J., Hornung, J.-P., Sibille, E., Underwood, M., Itohara, S., Dauer, W. T., et al. (2006) · Science · doi:10.1126/science.1123432 · Cited by 425
Kennedy, S. H., Konarski, J. Z., Segal, Z. V., Lau, M. A., Bieling, P. J., McIntyre, R. S., & Mayberg, H. S. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.778 · Cited by 420
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W., & Griffiths, R. R. (2012) · Journal for the Scientific Study of Religion · doi:10.1111/j.1468-5906.2012.01685.x · Cited by 405
Spirituality, Religion, and Depression in the Terminally Ill
Nelson, C. J., Rosenfeld, B., Breitbart, W., & Galietta, M. (2002) · Psychosomatics · doi:10.1176/appi.psy.43.3.213 · Cited by 399
BDNF release is required for the behavioral actions of ketamine
Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., & Duman, R. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu033 · Cited by 368
Psychedelics and mental health: a population study
Krebs, T. S., & Johansen, P.-Ø. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063972 · Cited by 347
Arrieta, Ó., Angulo, L. P., Núñez-Valencia, C., Dorantes-Gallareta, Y., Macedo, E. O., Martínez-López, D., Alvarado, S., Corona-Cruz, J.-F., & Oñate-Ocaña, L. F. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2793-5 · Cited by 346
Spirituality in the cancer trajectory
Puchalski, C. M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds088 · Cited by 343
Deakin, J. F. W., Lees, J., McKie, S., Hallak, J. E. C., Williams, S. R., & Dursun, S. M. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.37 · Cited by 311
Response and remission criteria in major depression – A validation of current practice
Riedel, M., Möller, H.-J., Obermeier, M., Schennach-Wolff, R., Bauer, M., Adli, M., Kronmüller, K., Nickel, T., Brieger, P., Laux, G., et al. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.03.006 · Cited by 288
Higher Expression of Serotonin 5-HT2A Receptors in the Postmortem Brains of Teenage Suicide Victims
Pandey, G. N., Dwivedi, Y., Rizavi, H. S., Ren, X., Pandey, S. C., Pesold, C., Roberts, R. C., Conley, R. R., & Tamminga, C. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.419 · Cited by 281
Treatment of existential distress in life threatening illness: A review of manualized interventions
LeMay, K., & Wilson, K. G. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.07.013 · Cited by 280 · cited 2×
“A number of manualized existentially oriented psychotherapies have been developed to address these existential/spiritual issues, with some empirical support from clinical trials (Lemay and Wilson, 2008), and several of these approaches were integrated into the therapy platform developed for this study.”
BackgroundDysfunctional Attitudes and 5-HT2 Receptors During Depression and Self-Harm
Meyer, J. H., McMain, S., Kennedy, S. H., Korman, L., Brown, G. M., DaSilva, J. N., Wilson, A. A., Blak, T., Eynan-Harvey, R., Goulding, V. S., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.90 · Cited by 264
Frokjaer, V. G., Mortensen, E. L., Nielsen, F. Å., Haugbol, S., Pinborg, L. H., Adams, K. H., Svarer, C., Hasselbalch, S. G., Holm, S., Paulson, O. B., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.07.009 · Cited by 242
Classic hallucinogens in the treatment of addictions
Bogenschutz, M. P., & Johnson, M. W. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.002 · Cited by 226
Bhagwagar, Z., Hinz, R., Taylor, M., Fancy, S., Cowen, P., & Grasby, P. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1580 · Cited by 214
Psychological Distress and Cancer Survival: A Follow-Up 10 Years After Diagnosis
Brown, K. W., Levy, A. R., Rosberger, Z., & Edgar, L. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000077503.96903.a6 · Cited by 213
LSD-Assisted Psychotherapy in Patients with Terminal Cancer
Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. (2017) · International Pharmacopsychiatry · doi:10.1159/000467984 · Cited by 209
Antidepressants for the treatment of depression in people with cancer
Ostuzzi, G., Matcham, F., Dauchy, S., Barbui, C., & Hotopf, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011006.pub2 · Cited by 183
The Human Encounter with Death
Grof, S., & Halifax, J. S. (1977) · DigitalGeorgetown (Georgetown University Library) · Cited by 164
Shelton, R. C., Sanders‐Bush, E., Manier, D. H., & Lewis, D. A. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.11.036 · Cited by 158
(1969) · PubMed · Cited by 150
Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
Li, X., Frye, M. A., & Shelton, R. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.198 · Cited by 144
Study of Lysergic Acid Diethylamide as an Analgesic Agent
KAST, E. C., & COLLINS, V. J. (1964) · Anesthesia & Analgesia · doi:10.1213/00000539-196405000-00013 · Cited by 142
Farb, N. A. S., Anderson, A. K., Bloch, R. T., & Segal, Z. V. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.03.009 · Cited by 141
Laoutidis, Z. G., & Mathiak, K. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-140 · Cited by 126
Grassi, L. G., Caruso, R., Hammelef, K., Nanni, M. G., & Riba, M. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.842542 · Cited by 115
The promise of ketamine for treatment‐resistant depression: current evidence and future directions
DeWilde, K. E., Levitch, C. F., Murrough, J. W., Mathew, S. J., & Iosifescu, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12646 · Cited by 103
Yamauchi, M., Miyara, T., Matsushima, T., & Imanishi, T. (2005) · Brain Research · doi:10.1016/j.brainres.2005.10.075 · Cited by 89
The current status of the platelet 5-HT2A receptor in depression
Mendelson, S. D. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00177-9 · Cited by 85
Rosenfeld, B. D., Pessin, H., Lewis, C., Abbey, J., Olden, M., Sachs, E., Amakawa, L., Kolva, E., Brescia, R. J., & BREITBART, W. S. (2011) · Psychological Assessment · doi:10.1037/a0021767 · Cited by 70
Meyer, J. H. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.285 · Cited by 68
Mallei, A., Baj, G., Ieraci, A., Corna, S., Musazzi, L., Lee, F. S., Tongiorgi, E., & Popoli, M. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv069 · Cited by 64
A comprehensive review of palliative care in patients with cancer
Jaiswal, R., Alici, Y., & BREITBART, W. S. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.868788 · Cited by 59
Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice
Dhonnchadha, B. Á. N., Hascoët, M., Jolliet, P., & Bourin, M. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(03)00179-7 · Cited by 57
Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies
Ross, S. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.04.002 · Cited by 55
Self-citation(1966) · PubMed · Cited by 53
Grob, C. S., Bossis, A. P., & Griffiths, R. R. (2013) · Psychological Aspects of Cancer · doi:10.1007/978-1-4614-4866-2_17 · Cited by 53
Self-citationHung, C., Liu, C., Wang, S., Yao, Y.-C., & Yang, C. (2011) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2011.617456 · Cited by 47
Reeves, G. M., Rohan, K. J., LANGENBERG, P. W., Snitker, S., & Postolache, T. T. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.003 · Cited by 40
Hsu, W.-L., Chung, H.-W., Wu, C.-Y., Wu, H.-I., Lee, Y., Chen, E.-C., Fang, W., & Chang, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.638023 · Cited by 40
Iovieno, N., Tedeschini, E., Ameral, V. E., Rigatelli, M., & Papakostas, G. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328340775e · Cited by 39
Cohen, H. (2005) · Depression and Anxiety · doi:10.1002/da.20087 · Cited by 39
Ripoll, N., Hascoët, M., & Bourin, M. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.07.013 · Cited by 37
Gómez‐Gil, E., Gastó, C., Carretero, M., Díaz‐Ricart, M., Salamero, M., Navinés, R., & Escolar, G. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.583 · Cited by 24
The four-plates test–retest paradigm to discriminate anxiolytic effects
Ripoll, N., Dhonnchadha, B. Á. N., Sebille, V., Bourin, M., & Hascoët, M. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2130-1 · Cited by 23
Abrupt Withdrawal of Antidepressant Treatment
Freedman, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10050783 · Cited by 17
Research works printed but not linked: 7
- Doblin R, 1991, J Transpersonal Psychol, 23, 1
- Kast E, 1966, Chic Med Sch Q, 26, 80
- Krebs TS, 2012, J Psychopharmacol, 26, 994
- Lepack AE, 2014, Int J Neuropsychopharmacol, 18, 1
- Pahnke WN, 1963, Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness
- Pahnke WN, 1969, Curr Psychiatr Ther, 9, 144
- VandeCreek L, 1999, Measures of religiosity, 442
Cited by
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
“Recent studies (Griffiths et al. 2016; Ross et al. 2016; Carhart-Harris et al. 2016), including the present one, help demonstrate the feasibility of treating patients with major depressive disorder with psilocybin plus psychological support.”
BackgroundResultInfluential
Metadata
- Authors
- Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L.
- Affiliations
- NYU Langone Health (US)
- Bellevue Hospital Center (US)
- Palo Alto University (US)
- New York University (US)
- Corresponding author
- Ross, Stephen
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-11-30
- Volume
- 30
- Issue
- 12
- Pages
- 1165-1180
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC5367551
- OpenAlex
- W2559739670
- Semantic Scholar
- 1129a840891b76fb9022b6e91d1e1f4d2dafcb04
- Cited by
- 1,698
- References
- 90
- Citations by year
- 2026: 184 · 2025: 239 · 2024: 264 · 2023: 239 · 2022: 224 · 2021: 182 · 2020: 144 · 2019: 64 · 2018: 88 · 2017: 52 · 2016: 15
- FWCI
- 97.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000038)
- National Center for Advancing Translational Sciences
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, cancer-related anxiety, cancer-related depression, mystical experience, psychotherapy, existential suffering, spiritual well-being, quality of life, attitudes toward death, hopelessness, demoralization, psychedelic therapy
- MeSH terms
- Adult, Aged, Anxiety, Depression, Double-Blind Method, Female, Hallucinogens, Humans, Male, Middle Aged, Neoplasms, Psilocybin, Psychotherapy, Quality of Life, Surveys and Questionnaires, Cross-Over Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.